Farydak® receives European approval as a treatment for myeloma

Novartis, the multi-national pharmaceutical company, has recently announced that the European Commission has approved Farydak (panobinostat) as a treatment for relapsed and/or refractory myeloma patients who have received at least two previous lines of treatment, including Velcade® (bortezomib) and an immunomodulatory drug. This is the first histone deacetylase (HDAC) inhibitor with epigenetic activity to be…

Details